SCHEMBL7531364

SCHEMBL7531364

CCCNc1ccc(Cl)cc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
POLB P06746 3/20 0.49
GAA P10253 2/20 0.49
THRB P10828 1/20 0.49
RECQL P46063 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CA1 P00915 1/20 0.43
CA14 Q9ULX7 1/20 0.43
MRGPRX4 Q96LA9 1/20 0.42
HPGD P15428 2/20 0.41
USP2 O75604 1/20 0.41
CRHR1 P34998 1/20 0.41
TP53 P04637 2/20 0.41
IDO1 P14902 1/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
XBP1 P17861 1/20 0.41
ALOX12 P18054 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7535112 0.84 POLB (0.47) LMNASMN1; SMN2POLBGAATHRB
SCHEMBL3317973 0.83 SMN1; SMN2 (0.56) LMNASMN1; SMN2POLBGAARECQL
SCHEMBL11246752 0.82 SMN1; SMN2 (0.59) LMNASMN1; SMN2POLBGAAMEN1
SCHEMBL18893491 0.82 LMNA (0.45) LMNASMN1; SMN2GAAIDO1MEN1
SCHEMBL25866513 0.82 ALDH1A1 (0.46) LMNASMN1; SMN2GAATHRBRECQL
Hydrochloric Acid SCHEMBL3399550 0.82 SMN1; SMN2 (0.54) LMNASMN1; SMN2POLBGAARECQL
SCHEMBL18893409 0.81 KMT2A (0.41) LMNASMN1; SMN2POLBGAAIDO1
SCHEMBL10887295 0.80 LMNA (0.58) LMNASMN1; SMN2GAAIDO1MEN1
SCHEMBL10396655 0.80 LMNA (0.46) LMNASMN1; SMN2GAACA1CA14
SCHEMBL11238762 0.80 FERMT2 (0.53) LMNASMN1; SMN2GAACA1CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020137740-A1 Aminothiazole derivatives, process for preparing them and pharmaceutical compositions containing them FONTAINE EVELYNE (FR) 2002-09-26 US disclosed
EP-0934290-B1 AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI SYNTHELABO (FR) 2002-04-17 EP disclosed
US-6344470-B1 Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same SANOFI-SYNTHELABO (FR) 2002-02-05 US disclosed
EP-0934290-A1 AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI (FR) 1999-08-11 EP disclosed
WO-1998015543-A1 AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI (FR) 1998-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137740-A1 Aminothiazole derivatives, process for preparing them and pharmaceutical compositions containing them CRHR1, ADRA1D, ADRB1 LMNA 4550/4885SMN1; SMN2 3734/4885POLB 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.